# Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

> **NCT00068718** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Hodgkin Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Therapeutic Allogeneic Lymphocytes

## Key facts

- **NCT ID:** NCT00068718
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068718, "Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00068718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*